대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Application of Kunxian Capsule in Idiopathic Membranous Nephropathy
저자	Jia Lv
출판정보	2024; 2024(1):
키워드
초록	Objectives: In order to investigate the efficacy of Kunxian capsule (KX) used in the treatment of idiopathic membranous nephropathy(IMN), we conducted a retrospective study of IMN patients who received KX,and used the molecular docking and network pharmacology methods to explore the potential mechanism of KX for IMN. Methods: A total of 39 patients who confirmed to have IMN by biopsy in the Second Hospital of Jilin University from March 2017 to March 2022 were collected and treated with KX 0.6g three times a day. The clinical parameters during treatment were gathered to evaluate efficacy by statistical analysis.We used the data include the bioactive component of KX from TCMSP and HERB database and the pathogenic targets of IMN from Genecards and OMIM database to construct protein-protein interaction (PPI) network to find the main ingredients of KX and the key targets for IMN,and verify the binding capacity between them by molecular docking. Results: There is a notable decline in 24-hour urine protein quantification with KX therapy. Baseline 24-hour urine protein quantification was 3.34 g/day (IQR 1.9-4.77); at 1, 3, and 6 months of treatment, it fell to 2.4 g/day (IQR 0.91-3.17; P＜0.001); 1.5 g/day (IQR 0.8-2.5; P＜0.001); and 0.7 g/day (IQR 0.28-1.61; P＜0.001). After six months of treatment, the albumin level increased from (33.63±5.17) g/L at baseline to (36.99±6.07) g/L (P＜0.001).The first three ingredients of KX in PPI network were quercetin,luteolin and kaempferol,and the first three targets were AKT1,IL6 and TNF. Conclusions: Kunxian capsule can effectively improve serum albumin and 24-hour urine protein levels in the treatment of IMN patients.Quercetin,luteolin and kaempferol are the three main ingredients of it to target the three key targets of IMN,including AKT1, IL6 and TNF.
원문(PDF)	PDF 원문보기

목록

위로가기